{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:02:52Z","timestamp":1784271772271,"version":"3.55.0"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":196,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004204","name":"Tongji University","doi-asserted-by":"publisher","award":["Sykyqd06001"],"award-info":[{"award-number":["Sykyqd06001"]}],"id":[{"id":"10.13039\/501100004204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004204","name":"Tongji University","doi-asserted-by":"publisher","award":["sykygd13101"],"award-info":[{"award-number":["sykygd13101"]}],"id":[{"id":"10.13039\/501100004204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004204","name":"Tongji University","doi-asserted-by":"publisher","award":["SY-XKZT-2025-1019"],"award-info":[{"award-number":["SY-XKZT-2025-1019"]}],"id":[{"id":"10.13039\/501100004204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To systematically review the efficacy and safety of dapagliflozin and sacubitril\/valsartan (SV) in patients with heart failure (HF) following percutaneous coronary intervention (PCI)\u2013treated acute myocardial infarction (AMI) and to provide evidence for clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seven electronic databases were systematically searched from their inception to July 25, 2024. Following literature screening, data extraction, and risk of bias assessment, 14 randomized controlled trials involving 1310 patients were included. A meta\u2010analysis was subsequently conducted using RevMan 5.4 and Stata 18.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Meta\u2010analysis results showed that dapagliflozin combined with SV was superior to the control in improving left ventricular ejection fraction (LVEF) (WMD\u2009=\u20093.79, 95% CI: 2.70\u223c4.87;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and reducing N\u2010terminal pro\u2010brain natriuretic peptide (NT\u2010proBNP) levels (WMD\u2009=\u2009\u221283.49, 95% CI: \u2212129.33\u223c\u221237.65;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0004). This combination also significantly reduced left ventricular end\u2010diastolic diameter (LVEDD) (WMD\u2009=\u2009\u22122.27, 95% CI: \u22123.64\u223c\u22120.90;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001), left ventricular end\u2010systolic diameter (LVESD) (WMD\u2009=\u2009\u22123.29, 95% CI: \u22123.98\u223c\u22122.59;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), left ventricular remodeling index (LVRI) (WMD\u2009=\u2009\u22120.08, 95% CI: \u22120.10\u223c\u22120.06;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and left ventricular mass index (LVMI) (WMD\u2009=\u2009\u22128.84, 95% CI: \u221212.25\u223c\u22125.43;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), while increasing the 6\u2010min walking distance (6MWD) (WMD\u2009=\u200951.74, 95% CI: 32.33\u223c71.14;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Compared with SV monotherapy, adding dapagliflozin reduced major adverse cardiovascular event (MACE) incidence (OR\u2009=\u20090.24, 95% CI: 0.15\u223c0.39;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). However, no significant difference in adverse drug events (ADEs) was observed. Subgroup analyses revealed no significant differences in NT\u2010proBNP (WMD\u2009=\u2009\u2212194.85, 95% CI: \u2212396.53\u223c6.82;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.06), LVEDD (WMD\u2009=\u2009\u22121.50, 95% CI: \u22123.90\u223c0.89;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.22), or the incidence of ADE (OR\u2009=\u20091.26, 95% CI: 0.74\u223c2.14;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.39) when the follow\u2010up duration was short (\u2264 12 w). Additionally, significant heterogeneity was observed across studies for most outcomes. However, this heterogeneity was markedly reduced in the long\u2010term follow\u2010up subgroup (\u2265 24 w), and the results were consistent with those of previous meta\u2010analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence suggests that early initiation of dapagliflozin combined with SV offers superior efficacy and cardiovascular benefits for patients with HF following PCI\u2010treated AMI. These benefits become increasingly evident with sustained treatment. Nevertheless, these conclusions warrant validation through more high\u2010quality evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/crp\/1274068","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:04:14Z","timestamp":1784268254000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin Augmentation of Sacubitril\/Valsartan Therapy in Patients With Heart Failure Following PCI\u2010Treated Acute Myocardial Infarction: A Meta\u2010Analysis of Clinical Efficacy and Safety"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-2506","authenticated-orcid":false,"given":"Tang","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5998-1526","authenticated-orcid":false,"given":"Huimin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7055-2206","authenticated-orcid":false,"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-358X","authenticated-orcid":false,"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6812","authenticated-orcid":false,"given":"Mu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"e_1_2_12_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2022.01.004"},{"key":"e_1_2_12_2_2","first-page":"4","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton J. S.","year":"2022","journal-title":"Circulation"},{"key":"e_1_2_12_3_2","first-page":"923","article-title":"Advances in Diagnosis and Treatment of Heart Failure After Myocardial Infarction","volume":"38","author":"Feng K. G.","year":"2022","journal-title":"Journal of Practical Medicine"},{"key":"e_1_2_12_4_2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.25175","article-title":"Review of Cardiogenic Shock After Acute Myocardial Infarction","volume":"327","author":"Dalzell J. R.","year":"2022","journal-title":"JAMA"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2018.09.004"},{"key":"e_1_2_12_6_2","first-page":"437","article-title":"Interpretation of Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024","volume":"40","author":"Xu D. L.","year":"2024","journal-title":"Journal of Clinical Cardiology"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.102"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.114.001785"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13677"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1289663"},{"key":"e_1_2_12_11_2","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"44","author":"McDonagh T.","year":"2023","journal-title":"European Heart Journal"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.40.11.8972"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1181473"},{"key":"e_1_2_12_14_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins J. P. T.","year":"2011"},{"key":"e_1_2_12_15_2","first-page":"92","article-title":"Observation on the Efficacy and Safety of Dapagliflozin Combined With Norepinephrine in Patients With Heart Failure After Emergency Interventional Treatment of Acute Myocardial Infarction","volume":"30","author":"Wang Y. J.","year":"2022","journal-title":"Clinical Research"},{"key":"e_1_2_12_16_2","first-page":"1410","article-title":"Effect of Combination Therapy With Dapagliflozin and Entresto on Heart Failure After Emergency Intervention in Patients With Acute Myocardial Infarction","volume":"38","author":"Sheng X.","year":"2022","journal-title":"Journal of Practical Medicine"},{"key":"e_1_2_12_17_2","article-title":"Efficacy of Dapagliflozin Combined With Sacubactril Valsartan Sodium in the Treatment of Patients With Heart Failure After Emergency PCI in Patients With AMI","author":"Pan W. Y.","year":"2022","journal-title":"Intelligent Medicine, Artificial Intelligence in Medicine"},{"key":"e_1_2_12_18_2","first-page":"970","article-title":"Effect of Dapagliflozin Combined With Entresto in the Treatment of Heart Failure After Emergency Interventional Therapy in Non-Diabetic Acute Myocardial Infarction Patients","volume":"15","author":"Su P.","year":"2023","journal-title":"Chinese Journal of Evidence-Based Cardiovascular Medicine"},{"key":"e_1_2_12_19_2","first-page":"52","article-title":"Effect Analysis of Combined Application of Dapagliflozin and Entresto in the Treatment of Acute Myocardial Infarction Complicated With Heart Failure After Interventional Operation","volume":"20","author":"Liu J. J.","year":"2023","journal-title":"Medical Innovation of China"},{"key":"e_1_2_12_20_2","first-page":"56","article-title":"Clinical Efficacy of Dapagliflozin Combined With Sacubactril Valsartan Sodium in the Treatment of Heart Failure After Emergency Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","volume":"19","author":"Wu Z. F.","year":"2024","journal-title":"China Journal of Pharmaceutical Economics"},{"key":"e_1_2_12_21_2","first-page":"954","article-title":"Clinical Trial of Dapagliflozin Combination With Sacubitril\/Valsartan Sodium in the Treatment of Patients With Heart Failure After Acute Myocardial Infarction Intervention","volume":"40","author":"Li M. M.","year":"2024","journal-title":"Chinese Journal of Clinical Pharmacology"},{"key":"e_1_2_12_22_2","first-page":"0017","article-title":"Effect of Dapagliflozin Combined With Entresto on Heart Failure in Patients With Acute Myocardial Infarction After Emergency Percutaneous Coronary Intervention","author":"Gao S. M.","year":"2024","journal-title":"Medicine and Health"},{"key":"e_1_2_12_23_2","article-title":"Effect of Dapagliflozin and Entresto on Heart Failure in Patients With Acute Myocardial Infarction After Emergency PCI","author":"Zheng J.","year":"2024","journal-title":"Health Guide"},{"key":"e_1_2_12_24_2","first-page":"53","article-title":"Effect of Sacubitril\/Valsartan Combined With Dapagliflozin on Cardiac Function and Prognosis After Emergency PCI in Patients With Acute ST-Segment Elevation Myocardial Infarction","volume":"42","author":"Lv G. L.","year":"2024","journal-title":"Chinese Health Care"},{"key":"e_1_2_12_25_2","first-page":"129","article-title":"Effect Evaluation of Sacubitril\/Valsartan Combined With Dapagliflozin on Heart Failure in Patients With Acute Anterior Myocardial Infarction After Emergency Percutaneous Coronary Intervention","author":"Duan T. T.","year":"2024","journal-title":"Health Literacy"},{"key":"e_1_2_12_26_2","first-page":"233","article-title":"Effect of Dapagliflozin Combined With Entresto on Heart Failure in Patients With Acute Myocardial Infarction After Emergency Percutaneous Coronary Intervention","volume":"48","author":"Liu H. G.","year":"2024","journal-title":"Guizhou Medical Journal"},{"key":"e_1_2_12_27_2","first-page":"171","article-title":"Clinical Study on the Treatment of Heart Failure Patients With Acute Myocardial Infarction After Interventional Intervention With Dapagliflozin Combined With Sacubactril Valsartan Sodium","volume":"6","author":"Tang T. T.","year":"2024","journal-title":"Med Tribe"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.21037\/qims-23-1079"},{"key":"e_1_2_12_29_2","first-page":"387","article-title":"The 6 min Walk Test: A Quick Measure of Functional Status in Elderly Adults","volume":"123","author":"Enright P. L.","year":"2003","journal-title":"Chest"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.111.243162"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/circimaging.115.004996"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2323"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2011.10.028"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.03.013"},{"key":"e_1_2_12_35_2","volume-title":"Effect of Sacubitril-Valsartan on the Prognosis of Patients With Acute Myocardial Infarction Complicated With Heart Failure After Primary PCI","author":"Ma Z.","year":"2022"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911303"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1548"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01429-5"},{"key":"e_1_2_12_39_2","first-page":"e1","article-title":"022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"28","author":"Writing Committee Members","year":"2022","journal-title":"Journal of Cardiac Failure"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suad106"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-026-10609-3"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1594861"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2025.09.023"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac210"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735"},{"key":"e_1_2_12_46_2","article-title":"Dapagliflozin Reduces Kidney Inflammation in Alport Syndrome by Inhibiting the Stimulator of Interferon Genes Pathway in Renal Tubular Epithelial Cells","volume":"7","author":"Zheng Q.","year":"2026","journal-title":"Kidney"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.768214"},{"key":"e_1_2_12_48_2","article-title":"Dapagliflozin Alleviates Myocardial Ischemia\/Reperfusion Injury by Reducing Ferroptosis via MAPK Signaling Inhibition","volume":"14","author":"Chen W.","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41066-3"}],"container-title":["Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crp\/1274068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crp\/1274068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crp\/1274068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:04:18Z","timestamp":1784268258000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crp\/1274068"}},"subtitle":[],"editor":[{"given":"Esha","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/crp\/1274068"],"URL":"https:\/\/doi.org\/10.1155\/crp\/1274068","archive":["Portico"],"relation":{},"ISSN":["2090-8016","2090-0597"],"issn-type":[{"value":"2090-8016","type":"print"},{"value":"2090-0597","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1274068"}}